The invention relates to a granulate containing 95 99 % of imatinib mesylate and 1 5% of a volatile liquid to a process of making a granulate of imatinib mesylate which process comprises wetting imatinib mesylate with a granulation liquid and granulating the mixture in a granulator followed by drying and optionally sieving and/or milling of the produced population of granules to a pharmaceutical composition for oral administration and for use in medicine.
